Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KNSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKNSAKiniksa Pharmaceuticals International$53.24-0.8%$49.40$25.70▼$59.87$4.13B0.17786,396 shs382,321 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKNSAKiniksa Pharmaceuticals International-0.76%-5.79%+23.70%+11.45%+103.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKNSAKiniksa Pharmaceuticals International$53.24-0.8%$49.40$25.70▼$59.87$4.13B0.17786,396 shs382,321 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKNSAKiniksa Pharmaceuticals International-0.76%-5.79%+23.70%+11.45%+103.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKNSAKiniksa Pharmaceuticals International 2.78Moderate Buy$60.8614.31% UpsideCurrent Analyst Ratings BreakdownLatest KNSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026KNSAKiniksa Pharmaceuticals International Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/6/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)4/29/2026KNSAKiniksa Pharmaceuticals International Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$62.00 ➝ $64.004/29/2026KNSAKiniksa Pharmaceuticals International CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $60.004/29/2026KNSAKiniksa Pharmaceuticals International WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$58.00 ➝ $59.004/29/2026KNSAKiniksa Pharmaceuticals International Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $57.004/28/2026KNSAKiniksa Pharmaceuticals International Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$58.00 ➝ $71.004/21/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)4/17/2026KNSAKiniksa Pharmaceuticals International Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/16/2026KNSAKiniksa Pharmaceuticals International WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$53.00 ➝ $58.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKNSAKiniksa Pharmaceuticals International$677.56M6.05$0.79 per share67.59$7.87 per share6.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKNSAKiniksa Pharmaceuticals International$59.01M$0.9059.1631.32N/A9.69%13.26%9.86%7/28/2026 (Estimated)Latest KNSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/28/2026Q1 2026KNSAKiniksa Pharmaceuticals International$0.18$0.27+$0.09$0.27$206.11 million$214.27 million2/24/2026Q4 2025KNSAKiniksa Pharmaceuticals International$0.29$0.17-$0.12$0.17$200.86 million$202.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKNSAKiniksa Pharmaceuticals InternationalN/A3.793.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKNSAKiniksa Pharmaceuticals International53.95%Insider OwnershipCompanyInsider OwnershipKNSAKiniksa Pharmaceuticals International51.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKNSAKiniksa Pharmaceuticals International22076.94 million36.95 millionOptionableKNSA HeadlinesRecent News About These CompaniesKiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of "Moderate Buy" by BrokeragesMay 23 at 2:47 AM | americanbankingnews.comKiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 23 at 2:43 AM | marketbeat.comKiniksa Pharmaceuticals Still Has Room to Run After 100% Rally...May 22 at 10:15 AM | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Raised to Hold at Zacks ResearchMay 20 at 7:39 AM | marketbeat.comKiniksa Pharmaceuticals International (KNSA) price target increased by 10.10% to 63.53May 14, 2026 | msn.comVanguard Group Inc. Acquires 49,802 Shares of Kiniksa Pharmaceuticals International, plc $KNSAMay 12, 2026 | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month High - Still a Buy?May 11, 2026 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Sells $3,137,953.04 in StockMay 6, 2026 | insidertrades.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider John Paolini Sells 58,424 SharesMay 5, 2026 | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High on Analyst UpgradeMay 5, 2026 | marketbeat.comKornitzer Capital Management Inc. KS Purchases New Shares in Kiniksa Pharmaceuticals International, plc $KNSAMay 4, 2026 | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Increased to Strong-Buy at Wall Street ZenMay 4, 2026 | marketbeat.comKiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue GuidanceMay 2, 2026 | uk.finance.yahoo.comKiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial ResultsMay 2, 2026 | finance.yahoo.comInsider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells 48,565 Shares of StockMay 2, 2026 | insidertrades.comSanj Patel Sells 48,565 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) StockMay 1, 2026 | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $115,635.41 in StockMay 1, 2026 | insidertrades.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $115,635.41 in StockApril 30, 2026 | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $1,217,601.44 in StockApril 30, 2026 | marketbeat.comSanj Patel Sells 483,654 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) StockApril 30, 2026 | marketbeat.comKiniksa Pharma Sentiment Improves As Healthcare Surprise Sparks InterestApril 30, 2026 | kalkinemedia.comKNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Kiniksa Pharmaceuticals Still Has Room to Run After 100% RallyBy Chris Markoch | May 23, 2026KNSA Company DescriptionsKiniksa Pharmaceuticals International NASDAQ:KNSA$53.24 -0.41 (-0.76%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$53.14 -0.10 (-0.19%) As of 05/22/2026 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
